Greenway Greenhouse Cannabis Corp. AI Stock Analysis
Want to see TSE:GWAY full AI Analyst Report?
Greenway Greenhouse Cannabis Corp. (GWAY) AI Stock Analysis
Greenway Greenhouse Cannabis Corp.
(CNQX:GWAY)
Low score driven primarily by weak financial performance with ongoing losses and high leverage, alongside bearish technical indicators and unattractive valuation metrics.
Greenway Greenhouse Cannabis Corp. (GWAY) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 10.69M
- Dividend Yield
- ―
- Average Volume (3M)
- 9,668
- Price to Earnings (P/E)
- -3.6
- Beta (1Y)
- 0.72
- Revenue Growth
- -1.41%
- EPS Growth
- -78.91%
- Country
- Canada
- Employees
- 10
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Greenway Greenhouse Cannabis Corp. Business Overview & Revenue Model
Company Description
Greenway Greenhouse Cannabis Corporation specializes in the cultivation, processing, and distribution of dried cannabis flower and kief. This company, established in 2018, operates out of Kingsville, Canada, and is a subsidiary of Sunrite Greenhouses...
How the Company Makes Money
Greenway Greenhouse Cannabis Corp. primarily makes money by selling cannabis produced at its cultivation operations into the Canadian regulated supply chain, with revenues largely tied to B2B/wholesale transactions rather than direct-to-consumer reta...
Greenway Greenhouse Cannabis Corp. Financial Statement Overview
Summary
Persistent net losses, weak 7.7% gross margins, high debt-to-equity of 2.17, negative ROE, and negative operating cash flow signal elevated financial risk and operational instability.
Income Statement
32NegativeBalance Sheet
18Very NegativeCash Flow
25Negative| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.06M | 7.45M | 8.95M | 5.23M | 5.62M | 1.98M |
| Gross Profit | 616.88K | 188.40K | 1.68M | -335.38K | 741.99K | 844.02K |
| EBITDA | 70.27K | 446.31K | 972.53K | -2.21M | -576.34K | -1.36M |
| Net Income | -3.06M | -2.56M | -2.06M | -4.72M | -2.61M | -2.92M |
Balance Sheet | ||||||
| Total Assets | 30.42M | 31.01M | 32.26M | 33.09M | 35.30M | 35.63M |
| Cash, Cash Equivalents and Short-Term Investments | 1.13M | 1.14M | 3.14M | 1.53M | 3.64M | 7.48M |
| Total Debt | 15.53M | 15.58M | 15.79M | 16.02M | 13.96M | 16.67M |
| Total Liabilities | 23.28M | 23.26M | 22.21M | 21.17M | 20.36M | 18.77M |
| Stockholders Equity | 7.14M | 7.75M | 10.05M | 11.92M | 14.95M | 16.86M |
Cash Flow | ||||||
| Free Cash Flow | -1.06M | -2.01M | 1.61M | -4.96M | -4.38M | -4.10M |
| Operating Cash Flow | -971.95K | -1.87M | 1.81M | -2.05M | 2.23M | -1.97M |
| Investing Cash Flow | -86.85K | -132.20K | -194.37K | -2.92M | 428.31K | -2.12M |
| Financing Cash Flow | 0 | 0 | 0 | 2.85M | -6.49M | 8.12M |
Greenway Greenhouse Cannabis Corp. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:GWAY, the sentiment is Negative. The current price of 0.08 is above the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.08, and below the 200-day MA of 0.13, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 44.70 is Neutral, neither overbought nor oversold. The STOCH value of 83.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:GWAY.
Greenway Greenhouse Cannabis Corp. Peers Comparison
Overall Rating
TSE:ROMJ58Neutral
TSE:LABS57Neutral
TSE:AVCN42Neutral
TSE:AYR.A40.1Neutral
TSE:PCLO39Underperform
TSE:GWAY38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 58Neutral | CAD 28.72M | -17.28 | -4.00% | ― | 16.66% | -1007.41% | |
| 57Neutral | CAD 27.77M | -10.00 | -7.66% | ― | -9.31% | 66.84% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 42Neutral | CAD 13.44M | -4.54 | -65.40% | ― | -3.32% | -34.15% | |
| 40Neutral | CAD 18.10M | -0.03 | -74.75% | ― | ― | ― | |
| 39Underperform | CAD 8.41M | -2.41 | 28.59% | ― | 0.90% | 57.73% | |
| 38Underperform | CAD 10.69M | -3.62 | -35.33% | ― | -1.41% | -78.91% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:GWAY | Greenway Greenhouse Cannabis Corp. | 0.08 | -0.10 | -55.56% | |
| TSE:AYR.A | Ayr Wellness Inc. | 0.15 | 0.00 | 0.00% | |
| TSE:LABS | Medipharm Labs (Otc) | 0.07 | 0.00 | 0.00% | |
| TSE:PCLO | Pharmacielo | 0.04 | 0.00 | 0.00% | |
| TSE:ROMJ | Rubicon Organics | 0.42 | -0.03 | -5.56% | |
| TSE:AVCN | Avicanna Inc | 0.10 | -0.14 | -59.18% |
Greenway Greenhouse Cannabis Corp. Corporate Events
Greenway boosts revenue and volumes as it refines premium cannabis portfolio
PositiveGreenway Greenhouse Cannabis Corp. reported first‑quarter fiscal 2027 net revenue of $2.23 million, up 38 per cent year over year, as grams sold reached a record 2.33 million. Despite a net loss of $659,893, the company delivered positive adjusted EB...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 27, 2026
